Cannabidiol dosage
Pro Research Analysisby 
Searched over 200M research papers for "cannabidiol dosage"
Cannabidiol Dosage: Insights from Recent Research
Cannabidiol Dosage in Clinical Populations
Cannabidiol (CBD) has shown potential in treating various medical conditions, but determining the effective dosage remains a challenge. A systematic review of 35 studies across 13 medical contexts revealed that effective CBD doses range from less than 1 mg/kg/day to 50 mg/kg/day, depending on the condition being treated . For instance, epilepsy, the most frequently studied condition, showed positive outcomes with an average dose of 15 mg/kg/day . However, conditions like diabetes, Crohn's disease, and chronic pain did not show significant improvements, possibly due to the lower average doses used (around 2.4 mg/kg/day) .
Cannabidiol for Cannabis Use Disorder
A phase 2a trial aimed to identify effective doses of CBD for treating cannabis use disorder. The study found that doses of 400 mg and 800 mg per day were more effective than placebo in reducing cannabis use, as evidenced by lower urinary THC-COOH:creatinine ratios and increased days of abstinence from cannabis . The 200 mg dose was deemed inefficacious and eliminated from the trial .
Safety and Tolerability of Cannabidiol
A Phase I trial assessed the safety and pharmacokinetics of CBD in healthy adults. The study found that CBD was generally well tolerated, with common adverse events being mild to moderate, such as diarrhea, nausea, headache, and somnolence . The trial also noted that CBD reached steady-state concentrations after approximately two days of twice-daily administration, with a terminal elimination half-life of around 60 hours .
Cannabidiol in Anxiety and Anxiety-Related Disorders
CBD has shown promise in managing anxiety and anxiety-related disorders. A systematic review of eight studies, including randomized controlled trials and case reports, found that CBD doses ranging from 6 mg to 400 mg per dose improved clinical outcomes in various anxiety assessment scales . The studies indicated that CBD was well tolerated, with minimal adverse effects like fatigue and sedation .
Cannabidiol Pharmacokinetics in Dogs
A study on the pharmacokinetics of CBD in dogs found that oral CBD-infused oil provided the most favorable pharmacokinetic profile, with higher systemic exposures compared to other formulations like microencapsulated oil beads and transdermal cream . The half-life of CBD after a 75 mg and 150 mg dose was approximately 200 and 128 minutes, respectively .
Enhanced Delivery Methods for Cannabidiol
A study evaluated a new delivery technology, TurboCBD™, which showed higher circulating CBD levels compared to generic CBD capsules. The TurboCBD™ 90 mg dose resulted in an 86% increase in circulating CBD levels at 90 minutes and a 65% increase at 120 minutes compared to the 90 mg control . This enhanced bioavailability was associated with increased cerebral perfusion and slight reductions in blood pressure .
Cannabidiol for Drug-Resistant Seizures in Tuberous Sclerosis Complex
A clinical trial involving 224 patients with tuberous sclerosis complex found that both 25 mg/kg/day and 50 mg/kg/day doses of CBD were effective in reducing seizure frequency. The 25 mg/kg/day dose was associated with fewer adverse events compared to the higher dose .
Cannabidiol in Advanced Cancer Symptom Management
A phase IIb study investigated the efficacy of CBD oil in reducing symptom distress in patients with advanced cancer. The study found no significant difference between CBD and placebo in reducing symptom distress scores over 14 days . The median effective dose selected by participants was 400 mg per day, with no correlation to opioid use .
Conclusion
The effective dosage of CBD varies widely depending on the medical condition being treated. While doses as low as 6 mg have shown efficacy in anxiety disorders, higher doses up to 50 mg/kg/day are required for conditions like epilepsy and tuberous sclerosis complex. CBD is generally well tolerated, with mild to moderate adverse effects. Enhanced delivery methods like TurboCBD™ may offer improved bioavailability, potentially allowing for lower effective doses. Further research is needed to standardize dosing strategies and optimize therapeutic outcomes across different medical contexts.
Sources and full results
Most relevant research papers on this topic